Overview

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

Status:
Completed
Trial end date:
2024-05-07
Target enrollment:
Participant gender:
Summary
To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.
Phase:
N/A
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Deoxyglucose
Fluorodeoxyglucose F18